Key Dates

Related Announcements

• October 21, 2022 - Avenir Award Program for Genetic or Epigenetic of Substance Use Disorders (DP1 Clinical Trial Optional) See Notice PAR-23-021 

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This is a Notice of Correction to the Key Dates information in PAR-23-021 “Avenir Award Program for Genetic or Epigenetics of Substance Use Disorders (DP1 - Clinical Trial Optional) ”

The following section of PAR-23-021 has been corrected:

Currently, it reads:

Section IV. Application and Submission Information

Letters of Reference:

Letters of reference are an important component of the application. Applicants must arrange to have three (and no more than three) letters of reference submitted on their behalf. Applications that are missing letters of reference will be considered incomplete and will not be reviewed. Late letters will not be accepted. Applicants are responsible for monitoring the submission of their letters to ensure that three letters have been submitted prior to the submission deadline. Applicants are encouraged to check the status of their letters in their Commons accounts.

Letters may be submitted beginning September 19 and must be submitted no later than 5:00 p.m. (local time of applicant organization), October 19.

Revised to read (in bold italics):

Section IV. Application and Submission Information

Letters of Reference:

Letters of reference are an important component of the application. Applicants must arrange to have three (and no more than three) letters of reference submitted on their behalf. Applications that are missing letters of reference will be considered incomplete and will not be reviewed. Late letters will not be accepted. Applicants are responsible for monitoring the submission of their letters to ensure that three letters have been submitted prior to the submission deadline. Applicants are encouraged to check the status of their letters in their Commons accounts.

Letters may be submitted beginning August 25 and must be submitted no later than 5:00 p.m. (local time of applicant organization), September 25.

All other aspects of PAR-23-021 remain unchanged.

Inquiries

Please direct all inquiries to:

Jonathan D. Pollock, Ph.D
National Institute on Drug Abuse
Telephone: 301-435-1309
Email: [email protected]

John Satterlee, Ph.D.
National Institute on Drug Abuse
Telephone: 301-435-1020
Email: [email protected]